full list rate price target
earn chang report pleas see
tabl page
last week abbott hillrom releas result kick earn across
med-tech sector view result combin preannounc earlier
month suggest gener stabil across med-tech
model updatesa summari chang present herein
report make model updat reflect preannounc
well latest think base commentari investor present
reduc pt reflect lower ev/sal multipl vs prior
revis sale vs prior encourag
appoint michael greiner cfo believ may challeng
street appreci moreov littl convict trajectori
earn cash flow histor med-tech stock characterist trade
ev/sal multipl ep street estim come
bloomberg still maintain underweight rate
who deck week edward other
januari confer call et
expect key focu organ growth quarter outlook
year manag expect organ sale growth high end
guidanc given manag commentari call regard
expect strong momentum continu would expect organ growth
guidanc rang believ consensu estim reason
expect focu knee spine franchis updat pend wright
medic acquisit maintain equal weight rate stock
januari confer call et
similarli expect focu organ growth caution manag
note call recent investor present sale growth expect
full year guidanc due tough comp potenti
salesforc disrupt plan expans channel chang model organ
sale growth manag also comment disrupt could impact
trend extent disrupt would overli concern long-
term stori firmli intact view maintain overweight rate
edward lifesci ew januari confer call et
expect focu transcathet aortic valv replac tavr
growth particularli given recent market debat around decemb volum
expect million ww underli basi us nearli
expect ew reiter guidanc net/net continu rate ew
share underweight believ share price tavr opportun
believ mitral opportun farther street appreci also
believ there lack potenti posit catalyst await uk court
decis abt-ew pascal ip litig case
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
co
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
result januari confer call et
result januari confer call et
result januari confer call et
result februari confer call et
result februari confer call et
fiscal result februari confer call et
fiscal result februari confer call et
result estimate februari confer call estimate et
publish follow note past sever week
hrc- kstew call note manag express confid outlook call
 kstew note nan investor brief highlights-market opportun today tomorrow
 kstew updat nan pain brain gain
abbott laboratori pass ceo baton abbott perhap best oper posit
 kstew call note mile white comment leav abbott perhap best posit
 anoth product approv month micra av bit earlier expect reiter overweight
 intern investig still overhang preannounc sort guid maintain equal weight
also quick updat investor present
axnx/ expect ce mark eu approv interstim micro surescan mri lead reiter overweight
plc join catalyst month club reiter overweight
 medic suppli devic prep book move neutral sector view stock select
 jama studi cast doubt talc-ovarian cancer scienc news reiter overweight
 friday mark eighth talc win year missouri
 strengthen digit surgeri robot program verb jv buy-out anoth reason like
johnson johnson last minut gift idea upgrad overweight
note earn releas bmo market open market close confer call time list eastern time
coverag barclay research inform compani provid inform purpos invest recommend barclay research
cover julian mitchel industri cover meehan life scienc tool diagnost cover steve valiquett
phg shlg de freg de/fmeg de cover hassan al-wakeel eu medic servic
result januari confer call et
focu listen call
revenu ep actual estim
perform rel guidanc expect particularli organ sale growth
expect ep fx expect neg impact ep
reflect guidanc also expect focu compani organ sale growth
quarter figur organ sale grew though benefit
estim sell day organ sale growth
octob manag comment expect come higher end
knee/mako trend knee repres total compani sale recon
mako capit servic book perform account disproportion amount
investor focu view refer us knee sale
expect roughli rate manag note
seen expect see materi impact robot competit zb rosa
nevertheless investor remain concern competit landscap place
robot global us total knee mako procedur approxim
y/i total mako procedur approxim
commerci organ structur realign spine neurotechnolog commerci
organiz realign put spine group presid orthoped
neurotechnolog group presid medsurg result impact busi
updat spine sale came softer street expect manag
attribut slower cross-sel scale ramp hire acquir busi
expect updat busi call
wright medic updat announc intent acquir wright novemb
expand extrem busi expect updat transact outlook
guidanc confer call ceo kevin lobo comment expect strong
sale momentum continu manag expect organ
sale growth come higher end guidanc rang think street
expect initi organ sale growth target least start target
announc wright deal manag note would achiev
oper margin target expans inclus wright still
expect continu deliv minimum adjust ep growth beyond
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
result januari confer call et
focu listen call
perform rel expect manag expect organ growth
full-year guidanc rang due tough comparison potenti salesforc
disrupt due plan expans channel chang expect organ sale
growth would bring full year approxim estim expect
sale come in-lin street estim quarter due potenti sale forc
disrupt contrast past sever quarter customarili beat
manag flag investor confer present mid-januari could
slight impact sale growth well manag addit expect gross margin
around recent trend expect ep would bring full year
toward upper end guidanc rang
guidanc novemb investor confer mid-januari manag note
remain confid abil achiev perform least in-lin longer-
term goal top line manag goal least mid-single-digit organ growth note
buffalo filter becom organ februari provid tailwind double-digit growth
manag flag mid-januari investor confer sale forc expans could
slight impact sale growth bottom line manag goal double-digit ep
growth manag believ deliv despit fx headwind like higher tax
rate believ buffalo filter accret help absorb headwind
buffalo filter updat februari acquir buffalo filter lead manufactur
surgic smoke evacu technolog sinc deal close compani rais sale
expect origin expect increment sale million latest
forecast call million sale rep took buffalo filter sale higher
sale level view credit view
revenu ep actual estim
ep surpris histori rel consensu
surgiquest updat januari acquir surgiquest airseal system
airseal system consist valve-fre trocar continu pressur sens integr
insuffl smoke evacu expect investor commentari focus around
sustain double-digit growth airseal busi within gener surgeri
new product past sever year manag refocus effort
new product within orthoped busi includ crystalview trushot
y-knot gener surgeri compani roll pediatr indic airseal system
juli recent launch new valueblu line surgic pencil expect manag
provid commentari new product could acceler sale growth beyond
sale surpris histori rel consensu
barclay medic suppli devic
februari acquir buffalo filter approxim million
buffalo filter lead manufactur surgic smoke evacu technolog
surgic smoke gener surgic procedur use
energy-bas devic cauter vessel vapor human tissu bodili
fluid smoke contain toxic chemic benzen toluen carbon
monoxid etc along aerosol pathogen small particl
absorb patient bodi laparoscop endoscop procedur
buffalo filter sale current base would expect
leverag intern commerci infrastructur acceler buffalo filter
januari complet acquisit surgiquest million
surgiquest main product airseal system airseal system consist
valve-fre trocar continu pressur sens integr insuffl
smoke evacu use robot laparoscop procedur
airseal continu growth driver grow doubl digit
result januari confer call et
revenu ep actual estim
focu listen call
result rel guidanc particularli transcathet aortic valv tavr edward
expect total sale billion adjust ep expect focu
tavr busi particularli robust result typic
season softer quarter given summer month well recent market concern
around procedu slowdown decemb edward anticip bolu demand follow
low-risk indic carri expect million underli
basi us nearli comparison tavr sale million
underli basi manag comment us tavr procedur growth
transcathet mitral tricuspid therapi tmtt sale like sequenti lower
model versu due edwardss field action/recal novemb
guidanc updat particularli tavr outlook edward provid guidanc
analyst day earli decemb expect compani reiter guidanc sale
billion underli growth tavr sale billion underli growth
growth critic sale million underli growth adjust
ep surpris histori rel consensu
updat tmtt pipelin tmtt consid ew next growth driver analyst day
edward note receiv fda approv start us studi sapien transept mitral
valv replac compani discuss design trial listen updat
trial design number arm random mitraclip and/or surgeri number patient
expect enrol timelin regard pascal repair edward expect complet enrol
clasp iid inoper degen mitral regurgit studi year-end
continu enrol clasp iif function mitral regurgit clasp iitr tricuspid
regurgit studi manag work redesign cardioband mitral regurgit
proceed random clinic trial
surgic structur heart expect updat harpoon mitral valv repair technolog
investor day decemb edward said anticip european approv year-end
previous expect approv continu delay like due slower
sale surpris histori rel consensu
barclay medic suppli devic
build enrol
redesign
proceed mitral rct
result februari confer call et
focu listen call
perform rel expect guidanc manag expect constant
currenc sale growth line weight averag market growth rate wamgr
estim constant currenc sale growth benefit
addit sell day plu also final sale certain inventori believ may
bone cement discount price product categori expect constant
currenc sale growth lower end rang note slightli tough
comp emea region benefit year ago rebat adjust estim
headwind overal result
knee perform rosa updat total compani sale knee zb import
product line key focu invest commun zb lose share
number year due mainli product gap well suppli constraint due
manufacturing/fda warn letter issu suppli constraint eas zb launch
persona revis system cementless knee roll rosa knee robot system
latter like attract attent call knee sale trend shown figur
benefit extra sell day constant currenc america sale
emea asia pacif ww expect deceler total knee
due part sell day also rebat adjust help emea
sale year ago quarter total compani basi
guidanc updat sinc earli zb note first year expect
consist durabl wamgr though believ invest
commun believ capabl deliv rang given perform
roll-out rosa forecast constant currenc growth respect gross
margin zb manag state expect see pressur gross margin given price
headwind absenc med-tech tax refund manag note call expect
similar level hedg gain extent chang could pressur gross margin
manag expect leverag sg help off-set gross margin result
modest oper margin expans said comment may decid invest back
busi extent opportun drive top line
 core stabil believ manag like look enhanc
overal wamgr compani listen commentari appetit
fda warn letters/suppli updat zb prepar fda re-inspect facil
time discret fda zb warn letter outstand well
listen updat inspect meet fda
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
result februari confer call et
focu listen call
addit detail organ revenu perform boston pre-announce januari organ
revenu growth guidanc manag cite weaker expect
cardiac rhythm manag sale constant currenc driven softer decemb
sale well electrophysiolog note commerci transit ahead new
product launch comment peripher intervent organ may look
soft perform line expect due tougher comparison manag
expect adjust ep within previous issu guidanc
guidanc june boston scientif provid long-rang plan goal
period includ organ revenu growth oper margin
expans double-digit adjust ep growth time btg acquisit close
manag expect btg accret ep industri present
mid-januari follow earn pre-announce manag said given
organ sale growth miss sale growth guidanc rang may bit wider ensur
deliver/beat base preliminari result boston scientif grew organ
sale organ growth goal still seem reason us
current model organ sale growth consist current
model adjust ep
product updat expect manag highlight product pipelin give investor
greater comfort abil deliv organ growth outlook highlight
believ import stock sentiment perspect
acur tavr manag expect ce mark european approv
us approv think like
polarx lumin cryo rf singl shot ablat cathet eu approv
btg integr updat expect focu quarter updat call well
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
boston scientif total compani sale million organ growth
rhythm neuro sale million organ growth
cardiovascular sale million organ growth
medsurg sale million organ growth
fiscal result februari confer call et
focu listen call
fiscal result rel expect novemb manag guid compar
constant currenc sale growth due softwar upgrad may push
time revenu within manag solut price headwind china tender process
drug-coat balloon pressur year-over-year ep expect rang
investor confer mid-januari manag comment saw strong first
quarter saw pick-up flu result may come upper end guidanc
guidanc updat bd provid guidanc novemb bd expect report
sale growth includ fx headwind compar constant currenc
growth division basi expect bd medic life scienc
intervent adjust ep expect
y/i includ headwind gore fx tariff
flu benefit previous note mid-januari bd comment saw initi pick-up
stronger expect start flu season typic benefit diagnost divis
meaning manag provid detail impact call
china updat emerg market led china highlight key sourc growth
howev manag note china sale weaker expect within
medic deliveri busi particular cathet flush product due price pressur
china tender process basic medic devic expect tender process carryov
bd still expect strong doubl digit growth within busi segment china
bd intervent expect manag provid updat pma file lutonix
below-the-kne btk note mid-januari would submit sooner rather
later manag agre statist analysi plan fda examin addit
data becton guidanc includ benefit btk us indic also expect
updat perform newer product includ wavelinq av venovo covera
medic manag system confer call manag note updat
alari softwar delay pump shipment mid-januari manag note resum
pump shipment plan also expect updat pump market dynam
bd patch bd work extern partner determin next step
program pump applic often discuss context type diabet
broader drug deliveri applic becton partnership drug compani
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
fiscal result februari confer call et
focu listen call
fiscal result rel guidanc expect expect overal organ
growth divis organ basi expect mitg rtg
growth cvg growth diabet expect flat slightli
though note expect strong double-digit ou growth off-set us busi
expect doubl digit due revenu deferr associ tech upgrad
program fx expect headwind manag expect slight improv
oper margin off-set currenc headwind ep expect rang
includ estim neg impact fx model mid-point
fiscal guidanc updat provid initi guidanc organ sale growth
along result may compani hasnt chang overal sale guidanc
under-perform diabet busi off-set better perform three
busi unit group current expect organ growth cvg
mitg rtg low-single-digit growth diabet rais
adjust ep guidanc initi current rang due debt
refinanc lower interest expens lower tax rate current
commentari put take medtron extra sell week
quantifi past impact top-lin growth rate quarterli annual basi
respect previous said ep impact
limit medtron top-lin benefit contribut new product
near-term pipelin updat expect manag provid updat pipelin
cvg medtron micra av recent receiv fda approv reveal linq ii icm approv
expect soon also expect forthcom approv next-gen icd/crt platform
expect updat eu launch diamondtemp rf ablat cathet
mitg focu hugo surgic robot system first man slightli delay
rtg expect commentari intelli dtm expect commentari percept db
interstim micro snm system given recent ce mark expect spring fda approv
diabet updat minim launch overal strategi cgm
leadership transit updat geoff martha take ceo end april expect
geoff provid updat thought ahead transit also expect sean salmon
took evp presid diabet provid thought divis
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
barclay medic suppli devic
medtron recent product launch pipelin
courtesi
result estimate februari confer call estimate et
focu listen call
perform rel expect manag comment quarter includ
extra sell day y/i disrupt suppli due shutdown third-parti
steril would off-set benefit million sale expect impact sale
surgic product intermitt urolog cathet oem product manag also
note expect steril impact per share impact bottom line
urolift sale updat view share trade urolift sale perform
outlook urolift sale million growth rate somewhat
help easier comp due voluntari product recal year ago said expect robust
sale growth ex-fx million would put year growth albeit
manag guidanc call expect manag provid guidanc
urolift sale forecast ex-fx also expect manag
provid updat urolift roll-out japanes market opportun
guidanc may issu long rang lrp cover
period period manag expect organ sale growth thu
over-deliv goal driven mainli success urolift manag current
guidanc constant currenc sale growth believ approxim organ
growth view invest commun expect manag guid rang
includ like view given expect continu strong growth
urolift well contribut full launch manta larg bore vascular closur devic
expect constant currenc growth lrp call gross margin
oper margin expect margin expans weight
period forecast oper margin op
margin reach low end lrp due continu need sale
market invest support top-lin growth model tax rate ep
pipelin manta larg bore vascular closur began full launch januari manag see
market opportun recent commentari investor present suggest
tri temper expect signific immedi market share gain rel
expec marketplac ez-plaz bla submiss target fda
ask addit test await updat time percuv laparoscop surgic
system still limit re-releas
 outlook serial acquir manag state continu
look target manag note size-agnost capac transact
billion size expect compani comment landscap
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
urolift sale million
anniversariesneotract vsi barclay medic suppli devic
revenu ep actual estim
focu listen call
perform rel expect updat system avano current full-year
guidanc organ sale emb continu disrupt
system roll-out model organ sale slightli full-
year adjust ep guidanc impli ep model
guidanc past two year avano manag revis guidanc lower
reflect number item though primarili relat impact weaker on-q pump sale gaap
earn cash flow also significantli reduc believ like
transit year avano expect modest organ growth
adjust ep fairli flat level
new cfo commentari decemb avano announc appoint michael
greiner svp cfo effect januari greiner join avano
serv evp cfo expect greiner comment initi thought sinc join
compani also expect manag comment may updat long-rang plan
outlook on-q estim on-q pump pump fill anesthet drug provid
pain relief post-surgeri repres approxim sale on-q sale
challeng past two year two reason drug shortag drug filler shut-down
drug avail improv avano work prefer filler shift hospit
combin two disrupt busi hospit sinc shift
protocol believ shift back hospit on-q may also unlik could
risk exist on-q usag given new drug therapi come market heron htx-
pdufa date march avano taken action help address market
prefer acquir summit medic electron infus pump enter
agreement bioq manufactur ready-to-us infus drug system
ep surpris histori rel consensu
intervent pain/coolief outlook estim intervent pain busi
sale coolief like half sale coolief grow doubl digit
tradit rf seen slower growth competit market place player
abbott system market launch
accurian system rf cool rf featur last year though alreadi ramp
abbott announc would launch new rf system also announc
would focus intervent pain
chronic compani like comment progress neom acquisit well
sale surpris histori rel consensu
endoclear also busi disrupt challeng
bloomberg dec period avail
barclay medic suppli devic
total compani sale growth estim adjust acquisit fx
pain manag sale growth adjust acquisit
histor provid medic devic segment histor provid medic devic segment detail barclay medic suppli devic
focu listen call
revenu ep actual estim
addit commentari pre-announce context around us market
launch januari axon announc preliminari result million us
ou well street expect time factset
bloomberg estim remind axon receiv fda approv
axon r-snm system septemb fecal incontin indic
receiv overact bladder urinari retent indic novemb axon
begin ship system unit state last week octob first commerci
implant perform octob thu result repres full
quarter expect manag provid updat account coverag procedur
time call
guidanc updat novemb manag acknowledg then-consensu revenu
estim cite million note intent achiev dont expect manag
provid formal guidanc expect express confid consensu expect
pipelin competit dynam axon sever product pipelin
next-gener devic would reduc recharg session month
expect
next-gener devic would allow patient exist lead receiv
non-recharg devic expect
competit front recent announc receiv ce mark interstim
micro recharg snm system surescan mri lead expect fda approv late
spring devic first sacral neuromodul snm devic sinc launch
interstim ii allow better compet axon expect
pipelin updat competit dynam highlight call
patent litig novemb file patent litig suit axon
 district court central district california claim axon lead infring four
patent ask court award damag infring includ
award trebl damag wil infring plu reason attorney fee also
ask court perman enjoin axon
barclay medic suppli devic
focu listen call
account investig januari baxter pre-announce result postpon
call presum analysi incorrect fx convent intra-compani transact
complet expect later end also think compani want
wait made progress intern investig relat certain intra-compani
transact allegedli undertaken purpos gener non-oper fx gain
avoid loss complet expect updat matter call well
full result rel pre-announce januari baxter pre-announce preliminari
sale billion time bloomberg billion barclay
sale grew report basi vs guidanc sale constant
currenc basi vs guidanc sale oper basi vs guidanc
segment medic deliveri end year huge quarter baxter estim
report growth constant currenc would bring year
estim constant currenc surpass goal year mani
includ doubt compani deliv
manag note benefit stronger flu season million renal grew
report cc grew report cc clinic nutrit grew
report cc advanc surgeri grew report cc help
competitor suppli shortag acut therapi grew report cc
declin report cc
manag also announc oper margin would guidanc
guidanc along pre-announce baxter issu guidanc expect
constant currenc report sale growth exclud pend seprafilm
acquisit oper margin expect compani lrp guidanc
baxter provid guidanc detail oper margin intern
investig fx on-going ep estim vs bloomberg
renal care/advanc american kidney health initi opportun updat baxter expect
fda clearanc theranova hemodialysi dialyz potenti add-on
payment avail clinic
manufactur capac well broader aakhi thought call
expect updat theranova
pharmaceut expect updat clari warn letter transit contract
manufactur also expect updat new product launch like myxredlin premix insulin
revenu ep actual estim
ep surpris histori rel consensu
sale surpris histori rel consensu
barclay medic suppli devic
note midpoint pre-announc rang
note midpoint pre-announc rang
pharmaceut ex-fx growth adjust clari
note midpoint pre-announc rang
acquisit recothrom preveleak barclay medic suppli devic
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight view share high-
qualiti growth asset believ compani
favor mix busi product
geograph perspect see medic devic
busi particularli diabet key driver
growth go forward believ growth profil
upsid case depend sever key factor
strong growth libr alin approv
adopt new product particularli within medic
devic abil drive margin expans
downsid case driven slower libre/alin
sale fx slowdown emerg market inabl
around likelihood healthcar reform
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ on-going
risk on-q franchis may pressur
earn leav compani short lrp
goal ip separ cost also
higher expect disrupt
like pressur outlook believ
street forecast high rate
upsid case could driven greater sale
growth greater margin expans cost
save success lead improv
outlook greater recoveri on-q busi
downsid could driven deceler sale
growth trend inabl achiev cost save
unsuccess pressur on-q
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight differenti product
believ axn penetr million sacral
neuromodul market r-snm system
axon readi hit ground run
experienc sale organ physician feedback
posit devic given financi opportun
stock valuat rate compani
upsid driver includ faster adopt r-snm
greater market share gain sacral
would acceler overal market growth
rate introduct new technolog
downsid could stem slower uptak
inabl manufactur suffici quantiti
interstim micro altern treatment oab
expect reset lower
believ appropri level near-
term ep growth significantli aid financi
engin share repurchas believ
warrant lower valuat multipl rel other
sector think risk/reward fairli
upsid case could driven gener
competit less expect greater
success bring new product market
greater-than-expect improv profit
accret
downsid case could driven greater-
pressur renal med deliveri fx rate
inabl drive pharma sale pharma price
inabl expand margin
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
co
equal weight believ bd continu
success integr bard achiev plan
revenu cost synergi view recent
pullback share drug-coat balloon
concern overreact see upsid
share consid bd sale
ep growth profil compani view
valuat attract
upsid case could driven better-than-
bard acquisit improv overal
growth rate btk indic and/or favor
fda letter updat june panel
downsid case could driven foreign
exchang stronger usd could pressur
expect sale legaci bard busi
slowdown emerg market growth inabl
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight one
highest sustain sale growth profil larg cap
med-tech compani number new
product across busi segment
provid above-averag growth expect
double-digit ep growth continu believ
premium valuat warrant given
expect growth
upsid case could driven new product
regulatori approv time greater traction new
product improv profit success
integr leverag acquisit
downsid case could driven delay
inabl receiv regulatori approv slower
uptak new product greater competit
pressur key area stent structur
heart greater-than-expect price pressur
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight success
execut turnaround posit deliv
mid-single-digit sale double-digit ep growth
view acquisit buffalo filter posit
enhanc underli growth rate
upsid case could driven continu
success drive mid singl digit sale growth
continu strengthen us orthoped
improv new product contribut
greater expect
downsid case could driven slowdown
organ growth comp becom difficult
slowdown hospit capit equip market
invest spend drive futur growth
foreign exchang rate strengthen us dollar
higher tax
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ sale growth like
slow edward face competit transcathet
aortic valv tavr expect limit leverag
edward invest transcathet mitral valv
tmvr/r opportun sale ep estim
street tmvr/r repres potenti
second act still risk like
upsid case may driven better-than-
expect tavr sale greater leverag
stronger uptak tmvr europ faster-
than-expect time tmvr/r product
downsid case may driven delay
inabl commerci tmvr/r technolog
slowdown tavr sale due market slowdown
and/or competit pressur fx rate
greater expens support tmvr/r
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ manag
right strategi chang portfolio mix creat
durabl mid singl digit sale doubl digit ep
growth profil compani howev stock re-
rate believ take time market get
comfort transform sustain
especi hospit capital-expenditure profil
rate driven new product introduct better-
than-expect margin improv
downsid case driver includ challeng
hospit capital-expenditure environ inabl drive
acceler top-lin growth increas
competit pressur dilut
overweight believ share like
trade fundament next
month trade closer peers/market
believ fundament solid pharma growth
strong driven darzalex imbruvica
stelara tremfya portfolio move posit
medtech/consum allow least
market growth
upsid driver includ capit deploy drive
faster growth greater success new drug
outcom greater margin expans
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commerci success medic devic
action drug/devic recal margin eros
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ
number new product across busi
allow sustain mid-single-digit growth
expect leverag provid
least high-single-digit ep growth believ
stock valuat still attract despit recent
appreci share
upsid case driver includ success
deploy market share gain key area
cardiovascular structur heart surgic
neurostimul greater margin expans
expect
inabl receiv product approv market
share loss key categori dilut deal
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
compani fundament believ share-pric
perform like restrain
outstand acquisit wright medic
on-going integr pend robot
competit knee zimmer biomet
growth greater success new product
greater success drive oper margin
downsid case driver includ slowdown
orthoped hospit capital-expenditure market increas
competit knee foreign exchang stronger
us dollar inabl drive margin expans
continu grow modestli deceler
success past deal notabl
neotract urolift vsi help acceler
overal growth believ sale growth
achiev warrant premium pe
stock current reflect equal weight
upsid case could driven greater urolift
vsi sale greater improv profit
improv core busi sale growth
rate accret
downsid case could driven slowdown
urolift sale rel expect challeng
within core busi foreign exchang rate
stronger us dollar higher interest rate
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight view appoint
bryan hanson ceo posit catalyst chang
believ orchestr turnaround
howev believ transform need
like take multipl year see prospect
signific sale margin expans
limit near-term
upsid case could driven improv
market trend orthoped greater success
improv price trend strateg
downsid case could driven inabl
receiv and/or execut new product approv
deterior price addit fda regulatori
exchang stronger us dollar dilut
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
valuat methodolog risk
valuat methodolog set price target primarili reli forward price-to-earnings methodolog believ stock
maintain premium multipl given top line bottom line growth prospect pt appli multipl ep
risk may imped achiev barclay research valuat price abbott signific exposur
emerg market intern broadli thu chang fx rate could pressur sale ep result new product central
posit view approv adopt new product therefor anoth risk risk includ healthcar reform effort medicar
reimburs chang product recal fda warn letter govern regulatori action libr signific driver
growth chang trajectori key risk factor
valuat methodolog price target base ev/sal multipl appli multipl sale estim
arriv valuat med-tech compani substanti question growth outlook histor trade revenu
risk may imped achiev barclay research valuat price risk includ approv
abil compani sustain least mid-single-digit growth time uptak new product abil realiz cost save
target off-set strand cost chang effect tax rate foreign exchang success deploy capit dilut
valuat methodolog valu axn ev/sal basi price target appli multipl sale estim
million compar smid cap high growth med-tech compani
risk may imped achiev barclay research valuat price risk includ time adopt
clinician abil penetr market competit product approv time line launch particularli interstim micro
fda manufactur issu recal also risk factor reimburs chang
valuat methodolog set price target primarili reli forward price-to-earnings methodolog pt appli target pe
ep estim
risk may imped achiev barclay research valuat price outcom account investig
key risk factor new product import baxter growth outlook therefor approv uptak new product key risk
factor gener competit particularli cyclo brevibloc could pressur earn and/or extent pressur less expect
favor impact fx rate stronger us dollar could also pressur baxter sale earn outlook risk includ signific
reimburs chang fda govern action
co
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
multipl calendar ep
risk may imped achiev barclay research valuat price upsid risk factor extent becton
success integr bard see greater expect revenue/cost synergi downsid fx stronger us dollar commod
cost could greater headwind risk factor includ time success new product increas competit key product
drug-coat balloon infus pump signific chang reimburs fda govern action
valuat methodolog valu share use price-to-earnings methodolog price target appli target pe
ep level similar stock current trade ep compar high growth larg cap med-tech
risk may imped achiev barclay research valuat price key risk upsid downsid
relat trajectori sale growth new product integr upsid risk includ greater success new product
healthcar reform litig outcom inabl drive margin expans inabl integr acquisit govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog believ multipl ew
share like compress given potenti slower growth believ harder increment penetr tavr market
tmtt opportun like take longer play price target appli price-to-earnings multipl ep estim
risk may imped achiev barclay research valuat price greater transcathet aortic valv
replac tavr sale success transcathet mitral tricuspid therapi tmtt could result higher earn expand price-to-earnings
risk factor includ new product approv particularli mitral valv competit product launch signific chang
reimburs product failur valv thrombosi advers long-term outcom may chang usag trend product patent
litig outcom fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli target
valuat methodolog risk
pe calendar ep estim slight discount med-tech compani trade
growth profil improv expect pe expand closer peer
risk may imped achiev barclay research valuat price downsid risk includ fx rate
strengthen us dollar could pressur earn stock perform new product key futur success compani
thu extent compani unabl receiv fda approv could advers impact futur outlook product includ
compani surgic robot platform expect regulatori approv outsid unit state begin key
product includ micra av interstim micro minim futur iter continu blood glucos monitor devic
transcathet valv system upsid greater success new product margin expans risk includ signific reimburs
chang competit pressur product failur fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli pe
multipl ep estim
risk may imped achiev barclay research valuat price fx rate recent acquisit could
pressur earn growth competit pressur particularli area knee competitor launch compet robotic-assist
system could impact growth outlook sentiment toward stock time ultim receipt new product approv could
affect outlook risk includ signific chang reimburs potenti dilut associ acquisit product failur
fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli pe
multipl ep estim premium market other med-tech sector believ
warrant given higher growth rate
risk may imped achiev barclay research valuat price upsid extent neotract urolift sale
higher expect could drive upsid sale earn lead higher pe downsid urolift sale disappoint core
growth fail improv fx stronger us dollar higher interest rate half debt float risk includ time receipt
new product approv competit pressur particularli key product like urolift signific chang reimburs fda
govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog appli multipl
adjust cash ep estim sinc zmh/zbh share trade average pe multipl high low
equat discount given compani growth profil believ discount med-tech sector warrant
multipl closer histor rel pe averag appropri
risk may imped achiev barclay research valuat price upsid resolut fda matter
acceler top line growth improv margin profil downsid delay new product approv failur see signific
increas new product uptak neg earn revis addit cost associ on-going manufactur issu risk factor
includ signific reimburs chang competit pressur dilut associ potenti acquisit integr acquir
busi proce sale busi fda govern action
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
